- Home
- PACS vs QGEN Comparison
PACS vs QGEN Comparison
Compare PACS & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PACS | QGEN |
|---|---|---|
| Founded | 2013 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 9.0B |
| IPO Year | 2024 | 1998 |
Fundamental Metrics
Financial Performance| Metric | PACS | QGEN |
|---|---|---|
| Price | $44.63 | $42.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | $45.50 | ★ $45.76 |
| AVG Volume (30 Days) | 575.2K | ★ 2.7M |
| Earning Date | 02-26-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 7.17% |
| EPS Growth | ★ 221.05 | N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | ★ $5,288,932,000.00 | N/A |
| Revenue This Year | $10.19 | $8.18 |
| Revenue Next Year | $8.58 | $5.71 |
| P/E Ratio | $45.98 | ★ $24.01 |
| Revenue Growth | ★ 29.32 | N/A |
| 52 Week Low | $8.98 | $32.53 |
| 52 Week High | $49.49 | $57.82 |
Technical Indicators
Market Signals| Indicator | PACS | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 54.48 | 45.80 |
| Support Level | $43.94 | $41.14 |
| Resistance Level | $45.75 | $42.33 |
| Average True Range (ATR) | 1.54 | 1.09 |
| MACD | 0.09 | -0.26 |
| Stochastic Oscillator | 76.43 | 19.74 |
Price Performance
Historical ComparisonAbout PACS PACS Group Inc.
PACS Group Inc is a post-acute healthcare company mainly focused on delivering skilled nursing care through a portfolio of independently operated facilities. The post-acute care ecosystem serves individuals who need additional help recuperating from acute conditions, illnesses, or serious medical procedures after getting discharged from the hospital. It also provides senior care, assisted living, and independent living options in some of the communities. The company has one reportable segment.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).